Clear All
785 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
HCPCS Generic Name Brand Name Strength SEER*Rx Category Major Drug Class Minor Drug Class Oral (Y/N) FDA Approval Year FDA Discontinuation Year CMS Effective Date CMS Discontinuation Date Status
Momelotinib Ojjaara Multiple Chemotherapy Enzyme Inhibitor JAK 1/2 Yes 2023 In Use
Nirogacestat Ogsiveo 50mg, 100mg, 150mg Ancillary Therapy Miscellaneous Agent Ɣ Secretase Inhibitor Yes 2023 In Use
C9155 Epcoritamab-bysp Epkinly 0.16mg Immunotherapy Monoclonal Antibody CD20, CD3 No 2023 Aug 28, 2023 Dec 7, 2023 No Longer Used
NA Quizartinib Vanflyta Multiple Chemotherapy Tyrosine Kinase Inhibitor FLT3 Yes 2023 In Use
J8502 Aprepitant Aponvie 1mg Ancillary Therapy Antiemetic Substance P/Neurokinin 1 No 2023 Mar 18, 2026 In Use
J9345 Retifanlimab-dlwr Zynyz 1mg Immunotherapy Checkpoint Inhibitor PD-1 No 2023 Aug 28, 2023 In Use
C9163 Talquetamab Talvey 0.25mg Immunotherapy T Cell Receptor (TCR) GPRC5D, CD3 No 2023 Dec 7, 2023 Apr 17, 2024 No Longer Used
J8611 Methotrexate (jylamvo) Jylamvo 2.5mg Chemotherapy Antimetabolite Folic Acid Analog Yes 2023 Jun 10, 2024 In Use
Niraparib and Abiraterone Akeega Multiple Chemotherapy Androgen Receptor Inhibitor, Enzyme Inhibitor CYP 17, PARP Yes 2023 In Use
Fruquintinib Fruzaqla 1mg, 5mg Chemotherapy Tyrosine Kinase Inhibitor VEGFR Yes 2023 In Use
C9165 Elranatamab-bcmm Elrexfio 1mg Immunotherapy Monoclonal Antibody BCMA, CD3 No 2023 Dec 7, 2023 Apr 17, 2024 No Longer Used
J3263 Toripalimab-tpzi Loqtorzi 1mg Immunotherapy Checkpoint Inhibitor PD-1 No 2023 Jun 10, 2024 In Use
J1323 Elranatamab-bcmm Elranatamab-bcmm 1mg Immunotherapy Monoclonal Antibody BCMA, CD3 No 2023 Apr 17, 2024 In Use
J2277 Motixafortide Motixafortide 0.25mg Ancillary Therapy Immunostimulant Stem cell mobilizer No 2023 Apr 17, 2024 In Use
C9145 Aprepitant Aponvie 1mg Ancillary Therapy Antiemetic Substance P/Neurokinin 1 No 2023 Mar 17, 2023 Mar 18, 2026 In Use
J9361 Efbemalenograstim alfa-vuxw Ryzneuta 0.5mg Immunotherapy Immunostimulant Granulocyte Colony-Stimulating Factor No 2023 Jun 10, 2024 In Use
Futibatinib Lytgobi 4mg Chemotherapy Tyrosine Kinase Inhibitor FGFR Yes 2023 In Use
J9248 Melphalan (Hepzato) Hepzato 1mg Chemotherapy Alkylating Agent Nitrogen Mustard No 2023 Apr 17, 2024 In Use
J9058 Bendamustine (Apotex) Bendamustine (Apotex) 1mg Chemotherapy Alkylating Agent Nitrogen Mustard No 2023 Jul 11, 2023 Sep 14, 2024 No Longer Used
NA Elacestrant Orserdu Multiple Hormonal Therapy Estrogen Receptor Antagonist ERɑ Yes 2023 In Use
J9321 Epcoritamab-bysp Epkinly 0.16mg Immunotherapy Monoclonal Antibody CD20, CD3 No 2023 Dec 7, 2023 In Use
J9259 Paclitaxel (American Regent) Paclitaxel (American Regent) 1mg Chemotherapy Antimitotic Agent Taxane No 2023 Jul 11, 2023 Dec 17, 2024 No Longer Used
J9286 Glofitamab-gxbm Columvi 2.5mg Immunotherapy Monoclonal Antibody CD20, CD3 No 2023 Dec 7, 2023 In Use
Capivasertib Truqap 160mg, 200mg Chemotherapy AKT Inhibitor AKT 1/2/3 Yes 2023 In Use
J9064 Cabazitaxel (Sandoz) Cabazitaxel 1mg Chemotherapy Antimitotic Agent Taxane No 2023 Aug 28, 2023 In Use
The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is truly not available.